Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York 10065, USA.
J Clin Invest. 2013 Sep;123(9):4010-22. doi: 10.1172/JCI69443. Epub 2013 Aug 15.
Mice deficient in Schnurri-3 (SHN3; also known as HIVEP3) display increased bone formation, but harnessing this observation for therapeutic benefit requires an improved understanding of how SHN3 functions in osteoblasts. Here we identified SHN3 as a dampener of ERK activity that functions in part downstream of WNT signaling in osteoblasts. A D-domain motif within SHN3 mediated the interaction with and inhibition of ERK activity and osteoblast differentiation, and knockin of a mutation in Shn3 that abolishes this interaction resulted in aberrant ERK activation and consequent osteoblast hyperactivity in vivo. Additionally, in vivo genetic interaction studies demonstrated that crossing to Lrp5(-/-) mice partially rescued the osteosclerotic phenotype of Shn3(-/-) mice; mechanistically, this corresponded to the ability of SHN3 to inhibit ERK-mediated suppression of GSK3β. Inducible knockdown of Shn3 in adult mice resulted in a high-bone mass phenotype, providing evidence that transient blockade of these pathways in adults holds promise as a therapy for osteoporosis.
Schnurri-3(SHN3;也称为 HIVEP3)缺失的小鼠表现出骨形成增加,但要将这一观察结果应用于治疗益处,需要更好地了解 SHN3 在成骨细胞中的作用方式。在这里,我们发现 SHN3 是 ERK 活性的抑制剂,它在成骨细胞中的 WNT 信号下游部分起作用。SHN3 中的 D 结构域基序介导了与 ERK 活性和成骨细胞分化的相互作用和抑制,并且敲入 Shn3 中的突变,该突变消除了这种相互作用,导致体内 ERK 异常激活和随后的成骨细胞过度活跃。此外,体内遗传相互作用研究表明,与 Lrp5(-/-)小鼠杂交部分挽救了 Shn3(-/-)小鼠的骨硬化表型;从机制上讲,这对应于 SHN3 抑制 ERK 介导的 GSK3β 抑制的能力。在成年小鼠中诱导性敲低 Shn3 导致高骨量表型,这为在成年期短暂阻断这些途径作为骨质疏松症的治疗方法提供了证据。